TP53 and glioblastoma: The depletion of the tumour suppressor, Krueppel-like factor 6 (KLF6), which acts as a negative NF-κB regulator, is also postulated to contribute to NF-κB activation in GBM [36], and so are perturbations of TP53 biology, including both the loss and activation of the TP53-encoded protein, p53 [37,38,39,40].